| Titre |
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GDC-0077 Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer |
| Protocole ID |
WO41554 |
| ClinicalTrials.gov ID |
NCT04191499 |
| Type(s) de cancer |
Sein |
| Phase |
Phase III |
| Stade |
Maladie avancée ou métastatique |
| Type étude |
Traitement |
| Médicament |
GDC-0077 + Palbociclib et Fulvestrant vs Placebo + Palbociclib et Fulvestrant |
| Institution |
CISSS DU BAS-SAINT-LAURENT
 HOPITAL REGIONAL DE RIMOUSKI
150 av. Rouleau, Rimouski, QC, G5L 5T1
|
| Ville |
Rimouski |
| Investigateur(trice) principal(e) |
Dr Arnaud Blanchet-St-Pierre
|
| Coordonnateur(trice) |
Isabelle Gagnon
418-724-3000 poste 8029
|
| Statut |
 Actif en recrutement |
| Critètes d'éligibilité |
- Confirmed diagnosis of HR+/HER2- breast cancer
- Metastatic or locally advanced disease not amenable to curative therapy
- Progression of disease during adjuvant endocrine treatment or within 12 months of completing adjuvant endocrine therapy with an aromatase inhibitor or tamoxifen
- Receiving LHRH agonist therapy for at least 2 weeks prior to Day 1 of Cycle 1 if pre/peri-menopausal
- Confirmation of biomarker eligibility (detection of specified mutation(s) of PIK3CA via specified test)
- Consent to provide fresh or archival tumor tissue specimen
- Measurable disease per Response Evaluation Criteria in Solid Tumors, Version 1.1; "bone-only" disease, even if considered measurable, is not eligible
- Eastern Cooperative Oncology Group Performance Status of 0 or 1
- Life expectancy of > 6 months
- Adequate hematologic and organ function within 14 days prior to initiation of study treatment
|
| Critètes d'exclusion |
- Metaplastic breast cancer
- Any history of leptomeningeal disease or carcinomatous meningitis
- Any prior systemic therapy for metastatic breast cancer
- Prior treatment with fulvestrant or any selective estrogen-receptor degrader
- Prior treatment with any PI3K, AKT, or mTOR inhibitor, or any agent whose mechanism of action is to inhibit the PI3K-AKT-mTOR pathway
- Type 2 diabetes requiring ongoing systemic treatment at the time of study entry; or any history of Type 1 diabetes
- Known and untreated, or active CNS metastases. Patients with a history of treated CNS metastases are eligible
- Active inflammatory or infectious conditions in either eye, or any eye conditions expected to require surgery during the study treatment period
- Symptomatic active lung disease, or requiring daily supplemental oxygen
- History of inflammatory bowel disease or active bowel inflammation
- Anti-cancer therapy within 2 weeks before study entry
- Investigational drug(s) within 4 weeks before randomization
- Prior radiotherapy to >= 25% of bone marrow, or hematopoietic stem cell or bone marrow transplantation
- Chronic corticosteroid therapy or immunosuppressants
- Pregnant, lactating, or breastfeeding, or intending to become pregnant during the study or within 60 days after the final dose of study treatment
- Major surgical procedure, or significant traumatic injury, within 28 days prior to Day 1 of Cycle 1
|
Groupe d'étude en oncologie du Québec